MaartenTaal University of NottinghamUnited Kingdom

MaartenTaal
Maarten Taal MBChB, MMed, MD, FCP(SA), FRCP Maarten graduated from the University of Cape Town Medical School, South Africa, in 1987. After completing his post-graduate training in internal medicine and nephrology at Groote Schuur Hospital, Cape Town, he joined the Laboratory of Kidney and Electrolyte Physiology at Brigham and Women’s Hospital, Boston, USA under the directorship of Barry M. Brenner, MD. His research focused on mechanisms underlying the progression of chronic kidney disease (CKD) and earned him a Doctor of Medicine degree. He subsequently moved to the United Kingdom. He was appointed Professor of Medicine at the University on Nottingham in 2014, where he leads the Centre for Kidney Research and Innovation. He is a Past President of the British Renal Society and current Chair of the International Network of CKD Cohorts. He is Editor-in-Chief of “Current Opinion in Nephrology and Hypertension”, Co-Editor for “Brenner and Rector’s The Kidney”, Academic Editor for “PLOS Medicine” and is on the Editorial Board for “American Journal of Kidney Diseases”.
Institution

Day 1 - Sunday April 14, 2024

Time Session
9 a.m.
10:30 a.m.
ElianaDina-Batlle Chairperson Dradina@mac.comHospital Metropolitano De Santiago Pontificia Universidad Católica Madre y MaestraDominican Republic
GustavoLaham Chairperson glaham@cemic.edu.arGustavo Laham, Sociedad Argentina de Nefrología (SAN)Argentina
OlynkaVega Chairperson olynkavega@hotmail.comInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico
  • Updates on Uremic Toxins
    ZiadMassy Speaker ziad.massy@apr.aphp.frGlobal Medical Director, AURA, Paris France
  • Bringing Nobel Prize Winning Discoveries in Oxygen Sensing to Nephrology Clinics
    Kai-UweEckardt Speaker kai-uwe.eckardt@charite.deDepartment of Nephrology and Medical Intensive CarGermany
  • A Look Forward: Clinical Implications of Translational Research in CKD-MBD
    HirotakaKomaba Speaker hkomaba@tokai-u.jpTokai University School of MedicineJapan
  • Challenges and Opportunities for Translating Anti-inflammatory Therapeutics into Treatments for Patients With Kidney Failure
    LauraDember Speaker ldember@pennmedicine.upenn.eduUniversity of Pennsylvania United States
  • Q/A
Hall E
10:30 a.m.
11 a.m.
JonathanBarratt Spotlight Speaker jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
Spotlight Stage 1 (exhibition hall)
11 a.m.
12 p.m.
AgnesFogo Chairperson agnes.fogo@vanderbilt.eduUnited States
GuillermoRosa Diez Chairperson guillermo.rosadiez@hospitalitaliano.org.arHospital Italiano de Buenos Aires; Argentinean Society of Nephrology; Latinoamerican Society of Nephrology and Hypertension; International Society of NephrologyArgentina
  • My Story
    VictoriaGray Speaker vwright_03@yahoo.comUnited States
  • CrisprCas9 Therapy for Sickle Cell Diseases: How Do We Go from Discovery to Equitable Availability of Gene Therapy for All? Hugh de Wardener Lecture
    Obiageli EuniceNnodu Speaker oennodu@gmail.comUniversity of AbujaNigeria
Hall A
12:15 p.m.
1:15 p.m.
JavierDe Arteaga Chairperson javierdearteaga@gmail.comHospital Privado Universitario de Cordoba. Catholic University from CordobaArgentina
KarinaProf Karina Soto Chairperson ksoto.nefro@gmail.comCentro Hospitalar de Setubal, EPE and CEDOC Universidade Nova de LisboaPortugal
SandraHerrmann Chairperson herrmann.sandra@mayo.eduMayo ClinicUnited States
  • AKI-related Cancer and Cancer Treatment-related TMA
    ClaraGarcía Carro Speaker claragarciacarro@hotmail.comSan Carlos Clinical Hospital (Madrid, Spain)Spain
  • AKI Related to Cancer Immunotherapy: Can Biomarkers Help?
    SebastianLapman Speaker lapseba@yahoo.com.arArgentina
  • Magnesium and AKI: Is There a Connection? From Bench to Bedside - What We Can Learn from Onconephrology
    JolantaMalyszko Speaker jolmal@poczta.onet.plMedical University of Warsaw, PolandPoland
  • Q and A
Hall E
3 p.m.
4 p.m.
FelipeInserra Chairperson felipe.inserra@gmail.comArgentina
YelenaDrexler Chairperson yrd6@miami.eduUniversity of Miami Miller School of MedicineUnited States
  • New Insights into the Mechanisms of Kidney Injury in the CRS
    WendyMccallum Speaker wmccallum@tuftsmedicalcenter.orgUnited States
  • Novel Pharmacological Treatments of the CRS
    MarkSarnak Speaker msarnak@tuftsmedicalcenter.orgTufts Medical CenterUnited States
  • Device-related Treatment for CRS
    ClaudioRonco Speaker cronco@goldnet.itInternational Renal Research Institute of VicenzaItaly
  • Q and A
Hall D
4:30 p.m.
5:30 p.m.
MaartenTaal Chairperson maarten.taal1@nhs.netUniversity of NottinghamUnited Kingdom
RobertoPecoits Filho Chairperson roberto.pecoits@arborresearch.orgArbor Research Collaborative for HealthUnited States
  • Big Data Lab
  • Patient-reported Outcome Measures: How Do Patients Experience CKD?
    AdeeraLevin Speaker alevin@providencehealth.bc.caCanada
  • Trial Simulation Using Observational Data
    AngeloKaraboyas Speaker angelo.karaboyas@arborresearch.orgArbor Research Collaborative for HealthUnited States
  • Using Routinely Collected Big Datasets for Clinical Research in CKD: Opportunities and Challenges
    DorotheaNitsch Speaker dorothea.nitsch@lshtm.ac.ukLondon School of Hygiene & Tropical MedicineUnited Kingdom
  • Q and A
Hall C4

Day 2 - Monday April 15, 2024

Time Session
11 a.m.
12 p.m.
Jose VicenteSanchez Polo Chairperson visanpolo@gmail.comRenal Division Social Security Institute. Nephrology Residence Program Coordinator, San Carlos University School of Medicine. Latin-American Society Of Nephrology (SLANH)Guatemala
MegJardine Chairperson meg.jardine@sydney.edu.auNHMRC Clinical Trials Centre, University of Sydney, AustraliaAustralia
  • Generative AI Revolution in Medicine
    MichalRosen-Zvi Speaker ROSEN@il.ibm.comhttps://research.ibm.com/Israel
  • Acceptance Speech by Awardee (Schrier Award), with Tasnuva Sarah Kashem (UK) and Farnaz Nobi (Bangladesh)
    Mohammad Shakib Uz ZamanArefin Speaker shakib04@yahoo.comBangladesh
Hall A
3 p.m.
4 p.m.
AlessiaFornoni Chairperson afornoni@med.miami.eduUnited States
MichelleRheault Chairperson rheau002@umn.eduUniversity of MinnesotaUnited States
  • Predicting the Risks of Kidney Failure and Death in Adults With Moderate-to-severe Chronic Kidney Disease (KDpredict)
    PietroRavani Free Communication pravani@ucalgary.caUniversity of CalgaryCanada
  • Plasma Exchange in ANCA Associated Vasculitis GN: Update After Pexivas – Recommendations and Updates
    Wladimir MietekSzpirt Speaker wladimir.mietek.szpirt.01@regionh.dkRigshospitalet, University of Copenhagen, Dept. of Nephrology, Denmark, Senior Research ConsultantDenmark
  • EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY: INTERIM RESULTS FROM THE PHASE 3 APPLAUSE-IgAN STUDY
    DanaRizk Free Communication drizk@uabmc.eduUniversity of Alabama at BirminghamUnited States
  • SPARSENTAN VS IRBESARTAN IN PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY (IgAN): SUBGROUP ANALYSES OF 2-YEAR RESULTS FROM THE PIVOTAL PHASE 3 PROTECT TRIAL
    JonathanBarratt Free Communication jb81@leicester.ac.ukUniversity of Leicester, Leicester, UKUnited Kingdom
  • PREGNANCY AMONG WOMEN ON CHRONIC DIALYSIS : THE FRENCH COHORT
    CécileCouchoud Free Communication cecile.couchoud@biomedecine.frREIN registry, Agence de la biomédecine, FranceFrance
Hall A
4:30 p.m.
5:30 p.m.
CarolineLamarche Chairperson caroline.lamarche.1@umontreal.caUniversité de MontréalCanada
Gustavo CristianGreloni Chairperson gustavo.greloni@hospitalitaliano.org.arArgentina
  • MGRS: Should All Forms Need Clonal Therapy?
    FrankBridoux Speaker f.bridoux@chu-poitiers.frDepartment of Nephrology and French Reference Center for AL amyloidosis and MGRS, University Hospital, Poitiers, FranceFrance
  • Renal Amyloidosis: What Is New?
    Veronica Torres CostaSilva Speaker veronica.torres@hc.fm.usp.brSão Paulo State Cancer Institute - University of São PauloBrazil
  • Can We Perform a Transplant in Patients with Myeloma and Amyloidosis?
    SabineKaram Speaker sabinejkaram@gmail.comUniversity of MinnesotaLebanon
  • Q and A
Hall A

Day 3 - Tuesday April 16, 2024

Time Session
9 a.m.
10:30 a.m.
Juan ManuelMejia Vilet Chairperson jmmejia@hotmail.comInstituto Nacional de Ciencias Médicas y Nutrición Salvador ZubiránMexico
ValeriaAlberton Chairperson vgalberton@gmail.comHospital Fernandez/ Hospital El CruceArgentina
  • Updates on IgAN Management
    HernánTrimarchi Speaker htrimarchi@hotmail.comHOSPITAL BRITÁNICO DE BUENOS AIRESArgentina
  • Membranous GN Classification and Management
    PierreRonco Speaker pierreronco@yahoo.frHôpital TenonFrance
  • MPGN Updates
    SanjeevSethi Speaker sethi.sanjeev@mayo.eduMayo ClinicUnited States
  • Managing Vasculitis
    RobertaFenoglio Speaker roberta.fenoglio@unito.itOspedale San Giovanni BoscoItaly
  • Q and A
Hall A
11 a.m.
12:15 p.m.
AlessiaFornoni Chairperson afornoni@med.miami.eduUnited States
Prof LizLightstone Chairperson l.lightstone@imperial.ac.ukImperial College LondonUnited Kingdom
MasaomiNangaku Chairperson mnangaku@m.u-tokyo.ac.jpJapan
  • Acceptance Speech: Bywaters Award
    MotokoYanagita Speaker motoy@kuhp.kyoto-u.ac.jpKyoto UniversityJapan
  • Insights into SGLT2 Inhibitors: A Story of Discovery. Donald Seldin Lecture
    EleFerrannini Speaker eleferrannini@gmail.comUniversity of PisaItaly
  • ELP2 Graduation
    MasaomiNangaku Speaker mnangaku@m.u-tokyo.ac.jpJapan
Hall A